Log in
Research at the University of Reading into the origin of acrylamide, a neurotoxin and probable human carcinogen, in cooked cereal and potato products has provided crucial information for the food industry and government agencies. This has enabled important mitigation strategies to be developed. When acrylamide was unexpectedly discovered in food in 2002, there was no explanation for its origin. Pioneering research at Reading showed that it was formed during heating from naturally-occurring sugars and the amino acid asparagine. Because of this knowledge it was then possible to investigate factors affecting acrylamide formation and develop methods of mitigation. Subsequently investigations were undertaken worldwide, including work at Reading, to minimise the problem.
Novel research into the cardiovascular and other health benefits of consuming flavanol-containing foods at the University of Reading prompted a multi-national food and confectionary producer, Mars Incorporated, to invest over £1.1 million in research into the absorption, metabolism and health effects of cocoa-derived flavanols in humans. This research informed the development of a cocoa-extract supplement drink and supplement extract, both widely available in the US since 2010. This in turn sparked interest from other multinational corporations looking to market flavanol- and other flavonoid-containing health products, resulting in an additional £917K investment by industry. Mars' cocoa-extract supplements currently hold a 1% share of all food and drinks marketed on a cardiovascular health platform in the US; a market worth US$3.1 billion in 2012. Research by Reading and others has provided evidence that consumption of these products can improve memory and cognition, cardiovascular health and digestive health for consumers. These and other research findings have been widely disseminated to the general public by the Reading researchers.
Professor William Stimson has led research into rapid diagnostic tests for the food industry from 1996 to the present day. These tests reduce the time for microbiological testing of food pathogens from 2-5 days to within a working day. The new technology is fully automated, uses less material and involves fewer manipulations than previously available kits, leading to a reduction in cost and time. A spin out company, Solus Scientific Solutions Ltd., has attracted €1.36M EUROSTARS funding for further Research & Development, and has created 24 jobs. Sales of testing kits produced revenue of £3.4 million by year end 2012, and have increased since this date.
Research conducted at the University of Bristol between 2002 and 2006 directly influenced a significant commercial decision about use of a food additive to aid appetite control, which protected consumers from an ineffective product. Concerns about increasing levels of obesity worldwide and the toll this takes not only on human health but on health care costs, have led to the development of food ingredients that satisfy hunger for longer (enhance satiety). One such major new ingredient, Fabuless, which is owned by DSM (Dutch State Mines), a leading global manufacturer of food ingredients, was being considered by Unilever for inclusion in its range of diet foods. DSM and Unilever contacted Professor Peter Rogers, who is known for his novel methods for the experimental study of appetite control, to test the effectiveness of Fabuless. Rogers demonstrated no satiety effect of Fabuless when consumed in realistic products, which caused Unilever to abandon Fabuless as a potential food ingredient in 2009. Publication of the research also meant that other food manufacturing companies and regulatory authorities were informed about the ineffectiveness of Fabuless.
A discovery that a tomato extract could help with healthy blood flow has been translated into a functional food ingredient now marketed globally via the spin-out company Provexis plc. Fruitflow® — Provexis' lead product — is the result of findings by researchers at the Rowett Institute of Nutrition and Health, now part of the University of Aberdeen, that biologically active constituents in tomatoes inhibit blood platelet aggregation: a known cause of heart attack, stroke and venous thrombosis. In 2009 Fruitflow® was the first food ingredient to meet the requirements of the European Food Safety Agency for products with a specific health claim. Provexis — the University of Aberdeen Rowett Institute spinout — is listed on the AIM market — the London Stock Exchange's international market for smaller growing companies — has seen values of £14 - £60 million and secured co-development agreements with major international partners, including DSM, Unilever and Coca-Cola. This case study demonstrates the direct translation of research to produce a functional food ingredient of interest to global market players.
The claimed impact therefore relates to development of new product, which has received the first ever novel health claim (Article 13.5) from the European Food Safety Authority, and is being marketed as novel food ingredient globally by a multinational company.
Since 1993 researchers from the University of Leeds (UoL) have devised robust and standardised experimental methodologies to study human appetite and food consumption objectively. Companies in the food and pharmaceutical sectors have used these procedures to develop functional foods and anti-obesity drugs. The validated methodologies also allowed global clinical research organisation Covance to establish its Human Appetite Laboratory to provide product evaluation for US and EU pharmaceutical companies. Food regulators have also recommended the Leeds approach for producing evidence to support appetite control claims for functional foodstuffs.
Imperial College research on the gut hormone, oxyntomodulin, showed it caused considerable weight loss in man. A powerful long acting analogue suitable for daily human administration (TKS1225) was developed. This was licensed by Imperial to a spinout, Thiakis Ltd, for successful human toxicity testing and then sold to Wyeth for $30 million initially and $120 million on meeting milestones. Wyeth Pharmaceuticals and the full legal agreement was subsequently acquired and developed by Pfizer in 2009.
The University of Nottingham (UoN) has developed two novel food-allowed additives based upon xanthan gum. The generation of these structurally modified forms allow xanthan to be used more efficiently in food manufacturing applications and provide nutritional and health benefits. The invention of the new xanthans benefits the global food industry by facilitating new product development and formulation.
Research by Professor Gary Williamson and researchers at the University of Leeds (UoL) has revealed new pathways of polyphenol absorption and metabolism in humans, including the effect of gut microflora on the bioavailability of these natural compounds found in coffee, having major impact on commerce. Output has provided the scientific evidence to support Nestlé's post-launch marketing for its Green Blend coffee. The UoL research supports Green Blend's key positioning as a "functional" coffee with health benefits because it delivers high levels of antioxidants to the body. The brand has estimated global sales of hundreds of millions of pounds per year.
Non-steroidal anti-inflammatory drugs (NSAIDs) are valuable analgesics, but cause dyspepsia, ulcers and hospitalisation (UK: 3,500pa, USA: 100,000pa) for complications that can lead to death (UK: 400-1,000pa, USA: 16,500pa). Acid inhibition by proton pump inhibitors (PPIs), the only widely accepted preventative strategy, was proposed and systematically proved by studies from Nottingham. NICE now recommends PPIs for all patients using NSAIDs and PPIs are central to all major international guidelines. PPI co-prescription has increased worldwide (from 27.6% in 2008 to 44.1% in 2012, in the UK); and reduces the risk of hospitalisation for gastrointestinal bleeding by 54% and symptomatic ulcer by 63%, thereby preventing up to 540 deaths per annum in the UK.